Trials / Completed
CompletedNCT01412177
OTO-104 for the Treatment of Meniere's Disease
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2b Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Otonomy, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OTO-104 | Single intratympanic injection of 12 mg OTO-104 |
| DRUG | Placebo | Single intratympanic injection of placebo |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2015-03-01
- Completion
- 2015-04-01
- First posted
- 2011-08-09
- Last updated
- 2015-09-03
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01412177. Inclusion in this directory is not an endorsement.